

### **Specialist information**

from the Committee for Anaesthesia (GV-SOLAS) in collaboration with Working Group 4 of the TVT

# The use of urethane in experiments with rodents and rabbits

March 2016

Authors: Kristianna Becker, Alessandra Bergadano, Eva Eberspächer, Jörg Haberstroh, Julia Henke, Martin Sager, Daniel Zahner, Margarete Arras, Veterinary Association for Animal Welfare (TVT) Working Group 4

### Table of contents

Urethane	3
Historical background and use in both human and veterinary medicine	3
Prior use in laboratory animals	4
Practical application: Preparation, storage, properties of injection solution, route of administration	4
Characterization of the anaesthetic: properties and side effects of anaesthesia	4
Summary and opinion	5
References	6

### Urethane

Other names:

- 0-Ethyl carbamate
- 0-Ethylurethane
- A 11032
- Carbamic acid ethyl ester
- Ethyl carbamate
- Ethyl urethane
- Leucethane
- Pracarbamine
- U-compound
- Urethane
- Urethanum
- X 41

Hazardous substance, labelling: hazard, toxic.

#### Carcinogenic, mutagenic >>> Occupational health and safety!

Chemical formula: C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>

General	information	based	on	internet	sources,	mainly	from
http://www.cł	nemie.de/lexikor	n/Urethan.ł	ntml				



Structural formula from wikipedia.org/wiki/Urethan

### Historical background and use in both human and veterinary medicine

Not used in clinical anaesthesia.

Not approved as either human or veterinary medicinal product.

Since urethane has not been used in clinical anaesthesia or in clinical veterinary medicine, information on its effects and the use of urethane in the scientific literature is extremely limited. The details on "Prior use in laboratory animals" and "Practical applications" were compiled on the basis of information from the literature and personal reports and experiences listed below.

### Prior use in laboratory animals

Prior use in laboratory animals under non-recovery conditions (death under anaesthesia without recovery of consciousness, acute experiment, terminal experiment, final study).

Used alone or in combination with other substances (frequently  $\alpha$ -chloralose) for general anaesthesia.

Long-term anaesthesia over several hours possible.

Minimal effect on respiration and cardiovascular system; therefore, suitable for physiological/pharmacological models under certain conditions

## Practical application: Preparation, storage, properties of injection solution, route of administration

- Produced by heating urea with alcohol under pressure, heating of urea nitrate with alcohol and sodium nitrite.
- Obtainable as colourless, odourless crystalline or white powder.
- Good solubility both in alcohol and in water (Branson 1995). Dissolved urethane is pH neutral, molecular weight 89, boiling point 182°C.
- Metabolizes to ammonia, CO<sub>2</sub>, and ethyl alcohol.
- The injection solution is produced by dissolving in H<sub>2</sub>O (1 mg/0.5 mL); a 10-20% solution is usually administered
- In principle, administration should be i.v., but i.p. is possible.
- Frequently in combination with α-chloralose because it increases the solubility of αchloralose. In addition, urethane reduces the undesirable CNS stimulation and muscle activity induced by α-chloralose.

### Characterization of the anaesthetic: properties and side effects of anaesthesia

Urethane induces a hypnotic state lasting 6-8 hours. Anaesthesia stage III1 with cardiovascular and respiratory stability (Erhardt et al. 2012).

Several authors also describe sufficient analgesic potential to urethane for surgical and other painful procedures (Fish et al. 2008).

Urethane has toxic effects on organ systems. After a few hours of anaesthesia, for example, haemolysis has been reported (Erhardt et al. 2012), as have renal dysfunction and many other pathological effects as a result of urethane injection (Fish et al. 2008).

Highly carcinogenic in mice, rats, and rabbits. Also, potentially carcinogenic for laboratory staff as a result of absorption through the skin.

No serious citable reports were found on the chronic use of urethane. Recovery from this state could be expected to last a long time and to be accompanied by short and long-term side effects relevant to animal welfare – probably not as a result of the toxicity of the substance

### Summary and opinion

### Mutagenic, carcinogenic! Occupational health and safety regulations!!!

Urethane is only used for long-term anaesthesia for very specific purposes in non-recovery experiments (death under anaesthesia without recovery of consciousness, acute experiment, terminal experiment, final study).

Ure than is injected i.p. or i.v., possibly also in combination with other substances (e.g.,  $\alpha$ -chloralose).

Urethane is not approved as a medicinal product and is not in clinical use. A lack of any readyto-use formulations means that injection solutions have to be prepared in the laboratory, posing an increased risk in its use. Aside from the potential risk to staff, considerable uncertainties for the anaesthesia and risks to the laboratory animal may arise as a result of errors or inattention in the preparation of the injection solution (e.g., with regard to concentration, solvent, solubility, contaminations, etc.).

### Urethane is carcinogenic and mutagenic. Occupational health and safety regulations borne in mind be considered when planning an experiment and strictly observed when working with urethane!

Urethane is explicitly no longer recommended for use and may only be used if no alternatives have been found after a thorough review of the situation. Furthermore, urethane may only be used in non-recovery experiments (death under anaesthesia without recovery of consciousness, acute experiment, terminal experiment, final study).

### References

- Erhardt W, Henke J, Haberstroh J, Baumgartner C, Tacke S (eds). 2012. Anästhesie und Analgesie beim Klein- und Heimtier mit Exoten, Labortieren, Vögeln, Reptilien, Amphibien und Fischen. 2nd edition. Schattauer, Stuttgart, Germany
- Field KJ, Lang CM. 1988. Hazards of urethane (ethyl carbamate): a review of the literature. Lab Anim 22:255-262.
- Field KJ, White WJ, Lang M. 1993. Anaesthetic effects of chloral hydrate, pentobarbitone and urethane in adult male rats. Lab Anim 27:258-269
- Fish RE, Brown MJ, Danneman PJ, Karas AZ (eds.). 2008. Anesthesia and Analgesia in Laboratory Animals. 2nd edition. Elsevier Academic Press, Amsterdam Boston, USA.
- Flecknell P (ed). 2009. Laboratory Animal Anaesthesia, 3rd edition. Elsevier Academic Press, London, UK.
- Green CJ. 1979. Animal Anaesthesia. Laboratory Animals Ltd, London, UK.

#### Disclaimer

The use and application of the publications (technical information, statements, booklets, recommendations, etc.) of the Gesellschaft für Versuchstierkunde GV-SOLAS and the implementation of the information and content contained therein is expressly at the user's own risk.

GV-SOLAS and the authors cannot accept any liability for any accidents or damage of any kind resulting from the use of the publication.

GV-SOLAS accepts no liability for damages of any kind arising from the use of the website and the downloading of templates. GV-SOLAS is also not liable for direct or indirect consequential damages, loss of data, loss of profit, system or production losses.

Liability claims against GV-SOLAS and the authors for material or immaterial damage caused by the use or non-use of the information or by the use of incorrect and/or incomplete information are fundamentally excluded.

Claims for damages against the Gesellschaft für Versuchstierkunde GV-SOLAS as well as against the authors are therefore excluded.

The works, including all content, have been compiled with the greatest scientific care. Nevertheless, GV-SOLAS and the authors do not assume any guarantee or liability for the topicality, correctness, completeness and quality of the information provided, nor for printing errors.

No legal responsibility or liability in any form can be assumed by GV-SOLAS and the authors for incorrect information and any resulting consequences.

Furthermore, the operators of the respective websites are solely responsible for the content of the websites printed in these publications.

GV-SOLAS and the authors have no influence on the design and content of third-party websites and therefore distance themselves from all third-party content.